Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells

Tan, Zhenya; Chen, Kan; Wong, Mandy; Sun, Minqiong; Liu, Yakun; Yang, Fan; Wang, Siying; Zheng, Hong

doi:10.3389/fcell.2022.857045

Cited by 12 publications

(8 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CXCL12/CXCR4 signaling pathway plays an important role in maintaining normal hematopoiesis, and is essential for the homing and bone marrow residence of AML and ALL cells ( 196 , 197 ). TA-MSCs can secrete a large amount of CXCL12 to activate the overexpressed specific receptor CXCR4 on AML cells, thereby guiding AML cells to migrate to the BMME and acquire drug resistance signals ( 196 ).…”

Section: Therapeutic Potential Of Targeting Mscs or Macrophagesmentioning

confidence: 99%

Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy

Li,

Nie,

Jin

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

As major components of the tumor microenvironment, both mesenchymal stem cells (MSCs) and macrophages can be remodelled and exhibit different phenotypes and functions during tumor initiation and progression. In recent years, increasing evidence has shown that tumor-associated macrophages (TAMs) play a crucial role in the growth, metastasis, and chemotherapy resistance of hematological malignancies, and are associated with poor prognosis. Consequently, TAMs have emerged as promising therapeutic targets. Notably, MSCs exert a profound influence on modulating immune cell functions such as macrophages and granulocytes, thereby playing a crucial role in shaping the immunosuppressive microenvironment surrounding tumors. However, in hematological malignancies, the cellular and molecular mechanisms underlying the interaction between MSCs and macrophages have not been clearly elucidated. In this review, we provide an overview of the role of TAMs in various common hematological malignancies, and discuss the latest advances in understanding the interaction between MSCs and macrophages in disease progression. Additionally, potential therapeutic approaches targeting this relationship are outlined.

show abstract

Section: Therapeutic Potential Of Targeting Mscs or Macrophagesmentioning

confidence: 99%

Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy

Li,

Nie,

Jin

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Exosomes derived from AML cells and AML-MSCs also play a role in altering the BM microenvironment [ 64 ]. They contain miRNAs that regulate gene expression in MSCs and contribute to leukemia cell survival [ 65 ].…”

Section: Mscs In Amlmentioning

confidence: 99%

“…Therapeutic strategies targeting MSCs in leukemia often focus on enhancing chemo-sensitivity and disrupting the protective microenvironment LSCs rely on. These strategies include the use of CXCL12/CXCR4 inhibitors, chemotherapy synergistic drugs, adhesion inhibitors, and bone homeostasis medicines [ 64 ]. CXCL12/CXCR4 inhibitors, such as plerixafor and other CXCR4 antagonists, have entered clinical trials, showing promise in disrupting the protective effects of MSCs on LSCs and increasing chemotherapy sensitivity [ 179 , 180 ].…”

Section: Potential Clinical Applications Of Mscs In Leukemiamentioning

confidence: 99%

Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia

Wu,

Weng,

et al. 2024

IJMS

View full text Add to dashboard Cite

This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within the bone marrow microenvironment and their impact on leukemia pathogenesis, progression, and treatment resistance. MSCs, characterized by their ability to differentiate into various cell types and modulate the immune system, are integral to the BM niche, influencing hematopoietic stem cell maintenance and functionality. This review extensively explores the intricate relationship between MSCs and leukemic cells in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. This review also addresses the potential clinical applications of MSCs in leukemia treatment. MSCs’ role in hematopoietic stem cell transplantation, their antitumor effects, and strategies to disrupt chemo-resistance are discussed. Despite their therapeutic potential, the dual nature of MSCs in promoting and inhibiting tumor growth poses significant challenges. Further research is needed to understand MSCs’ biological mechanisms in hematologic malignancies and develop targeted therapeutic strategies. This in-depth exploration of MSCs in leukemia provides crucial insights for advancing treatment modalities and improving patient outcomes in hematologic malignancies.

show abstract

“…The bone marrow microenvironment (BMM) is the basis for the survival of HSCs ( 17 ). Increasing evidence indicates that tumour-derived exosomes can remodel the BMM to a leukaemia-favourable microenvironment through the communication of biological information between HSCs and tumour cells ( 18 , 19 ).…”

Section: Regulatory Effect Of Exosomes On Bone Marrow Microenvironmentmentioning

confidence: 99%

Tumour‑derived exosomes and their emerging roles in leukaemia (Review)

et al. 2023

View full text Add to dashboard Cite

Exosomes are small vesicles with a diameter of ~40-100 nm that are secreted by the majority of endogenous cells under normal and pathological conditions. They contain abundant proteins, lipids, microRNAs, and biomolecules such as signal transduction molecules, adhesion factors and cytoskeletal proteins, and play an important role in exchanging materials and transmitting information between cells. Recent studies have shown that exosomes are involved in the pathophysiology of leukaemia by affecting the bone marrow microenvironment, apoptosis, tumour angiogenesis, immune escape and chemotherapy resistance. Furthermore, exosomes are potential biomarkers and drug carriers for leukaemia, impacting the diagnosis and treatment of leukaemia. The present study describes the biogenesis and general characteristics of exosomes, and then highlight the emerging roles of exosomes in different types of leukaemia. Finally, the value of clinical application of exosomes as biomarkers and drug carriers is discussed with the aim to provide novel strategies for the treatment of leukaemia.

show abstract

Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells

Cited by 12 publications

References 136 publications

Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy

Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy

Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia

Tumour‑derived exosomes and their emerging roles in leukaemia (Review)

Contact Info

Product

Resources

About